

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



HANGZHOU TIGERMED CONSULTING CO., LTD.

杭州泰格醫藥科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 3347)

ANNOUNCEMENT ON MAJOR OPERATING DATA FROM JANUARY TO FEBRUARY 2022

This announcement is made by Hangzhou Tigermed Consulting Co., Ltd. (the “**Company**”) pursuant to Rule 13.09(2)(a) and Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the inside information provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong)(as defined in the Listing Rules).

The Company and its subsidiaries are pleased to announce the major operating data from January to February 2022.

I. MAJOR OPERATING DATA FROM JANUARY TO FEBRUARY 2022

From January to February 2022, with the continuation of solid growth momentum, the principal business of the Company achieved steady growth. Based on the preliminary calculation of the Company, new bookings increased by more than 65% year-on-year, and the operating revenue increased by more than 100% year-on-year from January to February 2022.

II. DESCRIPTIONS

The above major operating data are preliminary calculation results from the finance department of the Company which are intended only as a progressive explanation for reference. Such data are unaudited and cannot be used for extrapolating the annual results of the Company.

The shareholders and investors of the Company are advised to beware of risks and exercise caution when dealing in the Company's securities.

By order of the Board
Hangzhou Tigermed Consulting Co., Ltd.
Ye Xiaoping
Chairman

Hong Kong, March 10, 2022

As at the date of this announcement, the executive directors of the Company are Dr. Ye Xiaoping, Ms. Cao Xiaochun, Ms. Yin Zhuan and Mr. Wu Hao; the independent non-executive directors of the Company are Mr. Zheng Bijun, Dr. Yang Bo and Mr. Liu Kai Yu Kenneth.